Welcome to our dedicated page for Insmed news (Ticker: INSM), a resource for investors and traders seeking the latest updates and insights on Insmed stock.
News and press releases about Insmed Incorporated (INSM) provide insight into the company’s progress as a global biopharmaceutical organization focused on serious and rare diseases. Insmed regularly issues updates on its commercial performance, clinical trial milestones, regulatory decisions, and corporate initiatives across its respiratory, immunology & inflammation, and neuro & other rare disease programs.
Recent news has highlighted key events such as U.S. Food and Drug Administration approval of BRINSUPRI (brensocatib) for non-cystic fibrosis bronchiectasis, European Commission approval of BRINSUPRI for specified NCFB patients in the European Union, and detailed business updates around the commercial launch of BRINSUPRI and continued global growth of ARIKAYCE (amikacin liposome inhalation suspension). Investors can also follow announcements on the advancement of TPIP (treprostinil palmitil inhalation powder) into Phase 3 studies for pulmonary hypertension associated with interstitial lung disease and other pulmonary indications.
Insmed’s news flow also covers clinical data readouts from studies such as ASPEN and WILLOW in NCFB, the BiRCh and CEDAR trials evaluating brensocatib in additional neutrophil-mediated diseases, and early-stage developments in gene therapy programs INS1201, INS1202, and INS1203. Corporate communications include financial results, conference presentations at major healthcare and respiratory congresses, and updates on acquisitions such as INS1148, an investigational monoclonal antibody for respiratory and inflammatory conditions.
For followers of INSM stock, this news page offers a centralized view of Insmed’s ongoing commercial execution, regulatory interactions, and pipeline evolution. Regular updates help track how the company’s therapies and investigational candidates are progressing through development and reaching patient populations worldwide.
Insmed (Nasdaq: INSM) has granted inducement awards to 27 new employees as of November 1, 2024. The awards consist of options to purchase a total of 66,740 shares of common stock at an exercise price of $68.32 per share, which was the closing price on Nasdaq Global Select Market on the grant date. These stock options have a 10-year term and follow a four-year vesting schedule: 25% vests after one year, followed by 12.5% vesting every six months until the fourth anniversary, contingent on continued employment.
Insmed (Nasdaq: INSM) has announced its participation in four major healthcare investor conferences in November 2024. The company will present at the Guggenheim Healthcare Innovation Conference in Boston (Nov. 11), UBS Global Healthcare Conference in Rancho Palos Verdes (Nov. 12), Wolfe Research Healthcare Conference in New York (Nov. 20), and Jefferies London Healthcare Conference in London (Nov. 21). All presentations will be webcast live through Insmed's investor relations website and archived for 30 days after the events.
Insmed (INSM) reported Q3 2024 financial results with ARIKAYCE revenue of $93.4 million, showing 18% growth year-over-year. The company maintained its 2024 global ARIKAYCE revenue guidance of $340-360 million. The quarter ended with approximately $1.5 billion in cash and equivalents. Key developments include the planned NDA submission for Brensocatib in Q4 2024 with potential U.S. launch in mid-2025, and a renegotiated term loan providing an additional $150 million. The company reported a net loss of $220.5 million ($1.27 per share) compared to $158.9 million ($1.11 per share) in Q3 2023.
Insmed (Nasdaq:INSM) has secured the #1 position in Science's 2024 Top Employers Survey for the fourth consecutive year. The survey, which gathered nearly 6,500 responses primarily from North America (65%), Europe (19%), and Asia/Pacific Rim (11%), evaluates companies in biotechnology and pharmaceutical industries.
The company stood out for its innovative leadership, respect for employees, social responsibility, and employee loyalty. With over 1,200 employees worldwide, Insmed has demonstrated strength in commercial and pipeline programs while maintaining its commitment to transforming patients' lives with serious diseases. The recognition highlights Insmed's distinctive culture and continued global expansion.
Insmed (INSM) held its third annual Global Day of Good, involving over 1,000 employees in volunteer activities across the U.S., Europe, and Japan. The company-wide service day supported more than 40 organizations globally, focusing on improving health, education, and human services. Activities included preparing kits for pediatric cancer patients, building playhouses, revitalizing community centers, packing food for pantries, sorting clothing donations, and translating children's books. Both remote and in-person volunteering options were available to ensure all employees could participate.
Insmed Incorporated (Nasdaq: INSM), a global biopharmaceutical company, has announced that it will release its third-quarter 2024 financial results on Thursday, October 31, 2024. The company will host a conference call for investors at 8:00 a.m. ET on the same day to discuss the financial results and provide a business update.
Shareholders and interested parties can participate in the conference call by dialing (888) 210-2654 (U.S.) or (646) 960-0278 (international) and using the access code 7862189. The call will also be webcast live on Insmed's website. A replay of the call will be available until November 7, 2024, and a webcast will be archived for 90 days on the company's website.
Insmed Incorporated (Nasdaq: INSM) presented positive late-breaking subgroup data from the Phase 3 ASPEN study of brensocatib in patients with non-cystic fibrosis bronchiectasis at the CHEST 2024 Annual Meeting. The subgroup analyses showed consistent positive impact on the rate of exacerbations across most prespecified subgroups, aligning with the overall trial results. Notably, brensocatib 25 mg demonstrated a reduced decline in lung function (FEV1) at Week 52 versus placebo for all prespecified subgroups.
The drug was well-tolerated, with common adverse events including COVID-19, nasopharyngitis, cough, and headache. Insmed plans to file a New Drug Application with the FDA in Q4 2024, aiming for a U.S. launch in mid-2025 and European and Japanese launches in H1 2026. If approved, brensocatib would be the first approved treatment for bronchiectasis and the first approved DPP1 inhibitor.
Insmed Incorporated (Nasdaq: INSM) has announced the granting of inducement awards to 52 new employees in accordance with NASDAQ Listing Rule 5635(c)(4). The awards, approved by Insmed's Compensation Committee, were made as a material inducement to each employee's entry into employment with the Company.
On October 1, 2024, the new employees received options to purchase an aggregate of 106,160 shares of Insmed common stock at an exercise price of $72.88 per share, which was the closing trading price on the Nasdaq Global Select Market on the date of grant. The options have a 10-year term and a four-year vesting schedule, with 25% vesting on the first anniversary and 12.5% vesting every six months thereafter through the fourth anniversary, subject to continued service with Insmed.
Insmed Incorporated (Nasdaq: INSM) has announced the granting of inducement awards to 60 new employees, approved by the company's Compensation Committee in accordance with NASDAQ Listing Rule 5635(c)(4). On September 3, 2024, the employees received options to purchase a total of 137,140 shares of Insmed common stock at an exercise price of $73.31 per share, which was the closing trading price on the Nasdaq Global Select Market on the grant date.
The options have a 10-year term and a four-year vesting schedule. 25% of the shares will vest on the first anniversary of the grant date, followed by 12.5% vesting every six months thereafter until the fourth anniversary, subject to the employee's continued service with Insmed.
Insmed reported Q2 2024 financial results with ARIKAYCE total revenue of $90.3 million, reflecting 17% growth over Q2 2023. The company reiterated its 2024 global ARIKAYCE revenue guidance of $340-$360 million. Key highlights include:
1. U.S. launch readiness for Brensocatib in Bronchiectasis on track with NDA submission expected in Q4 2024.
2. Primary endpoint for ENCORE study of ARIKAYCE agreed upon with FDA.
3. Positive topline data from Phase 3 ASPEN study of Brensocatib reported in May 2024.
4. Q2 2024 net loss of $300.6 million, or $1.94 per share.
5. Cash and cash equivalents of $1,246.8 million as of June 30, 2024.